Trial Profile
Immunogenicity and reactogenicity of diphtheria-tetanus vaccine GC1107 in Korean subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2018
Price :
$35
*
At a glance
- Drugs GC 1107 (Primary) ; Diphtheria-tetanus vaccine
- Indications Diphtheria; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 09 Mar 2011 New trial record